Furthermore, evidence is lacking on the ability of VEGF family members to predict benefit from specific treatments, especially on their predictive value for bevacizumab use.
This prediction, in part, addresses the criticisms of Whitley et al. [ 22] and Emberson et al. [ 23] that predictions made by tools like the S-TPI and our DAM always predict benefit, they do identify patients where that benefit is very small.
Thus, it is important to identify factors among the older population that predict benefit from ICU treatment, establish prognostic factors for long-term survival, and elucidate the HRQOL.
While clinical and pathologic features to predict benefit are valuable, the use of molecular techniques to better determine which tumors will benefit from chemotherapy is expected to further improve outcomes, reduce long-term complications, and provide cost-effective care.
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene predict benefit from tyrosine kinase inhibitors in patients suffering from non-small-cell lung cancer.
While biomarkers including PD-L1 expression, PD-L2 expression and the interferon-gamma gene signature show potential to predict benefit from checkpoint inhibitor therapy – it is hoped that improved understanding of the genomic and immune landscape will lead to ways to improved strategies to stratify patients and to select which HNSCC are most likely to benefit from these therapies.
The clinical utility of CTCs or HER2-positive CTCs in early BC for patient stratification and as biomarkers to predict benefit from secondary adjuvant treatment interventions with agents like biphosphonates or anti HER2 agents should be prospectively tested.
EndoPredict did not, however, predict benefit from adding paclitaxel.
Biomarkers are required to predict benefit from the different approaches to individualise treatment.
High heregulin levels predict benefit from patritumab treatment in patients with NSCLC.
However, extracellular domain HER2 (HECD ECD) baseline serum did not predict benefit from lapatinib.
